Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -163.18% is 44% below its 5-year average of -113.59%, around the middle of its 5-year range (-398.10%–-30.36%).
As of the fiscal period ended Sunday, May 31, 2026. 27.82% above its 12-month average of -226.09%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-05-31): -163.18%.
RETURN ON EQUITY (ROE)
-163.18%
RETURN ON EQUITY (ROE) AVG TTM
-226.09%
RETURN ON EQUITY (ROE) AVG 3Y
-140.04%
RETURN ON EQUITY (ROE) AVG 5Y
-113.59%
RETURN ON EQUITY (ROE) AVG 10Y
-133.43%
RETURN ON EQUITY (ROE) AVG 15Y
-117.03%
RETURN ON EQUITY (ROE) AVG 20Y
-87.30%
CURRENT VS TTM AVG
+27.82%
CURRENT VS 3Y AVG
-16.53%
CURRENT VS 5Y AVG
-43.66%
CURRENT VS 10Y AVG
-22.30%
CURRENT VS 15Y AVG
-39.43%
CURRENT VS 20Y AVG
-86.93%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-288.44%
vs the sector median at left
Lexaria Bioscience Corp.
Market Cap
$4.83M
Return on Equity (ROE)
-163.18%
TTM Avg
-226.09%
3Y Avg
-140.04%
5Y Avg
-113.59%
Market Cap
$4.81M
Return on Equity (ROE)
-40.76%
TTM Avg
-51.09%
3Y Avg
-48.10%
5Y Avg
-52.04%
Market Cap
$4.90M
Return on Equity (ROE)
-30.74%
TTM Avg
235.96%
3Y Avg
-836.91%
5Y Avg
-570.34%
Market Cap
$5.04M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
Market Cap
$4.60M
Return on Equity (ROE)
-385.27%
TTM Avg
175.03%
3Y Avg
3.40%
5Y Avg
-11.76%
Market Cap
$4.59M
Return on Equity (ROE)
-54.15%
TTM Avg
0.37%
3Y Avg
-1.09%
5Y Avg
-10.37%
Market Cap
$5.08M
Return on Equity (ROE)
-351.30%
TTM Avg
-321.98%
3Y Avg
-228.03%
5Y Avg
-177.46%
Market Cap
$5.12M
Return on Equity (ROE)
-4165.92%
TTM Avg
61.14%
3Y Avg
-23.12%
5Y Avg
-18.15%
Market Cap
$4.51M
Return on Equity (ROE)
-239.95%
TTM Avg
-454.28%
3Y Avg
-297.70%
5Y Avg
-194.53%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $4.83M | -163.18% | -226.09% | -140.04% | -113.59% |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.81M | -40.76% | -51.09% | -48.10% | -52.04% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.90M | -30.74% | 235.96% | -836.91% | -570.34% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.04M | -248.66% | -110.63% | -33.84% | -33.84% |
| CalciMedica, Inc. (CALC)vs › | $4.60M | -385.27% | 175.03% | 3.40% | -11.76% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.59M | -54.15% | 0.37% | -1.09% | -10.37% |
| Imunon, Inc. (IMNN)vs › | $5.08M | -351.30% | -321.98% | -228.03% | -177.46% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.12M | -4165.92% | 61.14% | -23.12% | -18.15% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.51M | -239.95% | -454.28% | -297.70% | -194.53% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A | 383.38% | 131.31% | 101.98% |
ROE
-163.2%
ROA
-161.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-05-31 | -163.18% |
| 2026-02-28 | -144.34% |
| 2025-11-30 | -219.69% |
| 2025-08-31 | -398.10% |
| 2025-05-31 | -205.16% |
| 2025-02-28 | -131.33% |
| 2024-11-30 | -74.89% |
| 2024-08-31 | -72.11% |
| 2024-05-31 | -47.91% |
| 2024-02-29 | -83.42% |
| 2023-11-30 | -162.68% |
| 2023-08-31 | -218.94% |
| 2023-05-31 | -156.82% |
| 2023-02-28 | -138.81% |
| 2022-11-30 | -112.30% |
| 2022-08-31 | -91.45% |
| 2022-05-31 | -76.01% |
| 2022-02-28 | -62.45% |
| 2021-11-30 | -45.58% |
| 2021-08-31 | -30.36% |
| 2021-05-31 | -34.45% |
| 2021-02-28 | -20.12% |
| 2020-11-30 | -198.22% |
| 2020-08-31 | -155.79% |
| 2020-05-31 | -134.85% |
| 2020-02-29 | -218.51% |
| 2019-11-30 | -170.47% |
| 2019-08-31 | -172.02% |
| 2019-05-31 | -133.30% |
| 2019-02-28 | -233.61% |
| 2018-11-30 | -196.87% |
| 2018-08-31 | -276.31% |
| 2018-05-31 | -230.11% |
| 2018-02-28 | -107.61% |
| 2017-11-30 | -85.47% |
| 2017-08-31 | -62.18% |
| 2017-05-31 | -45.85% |
| 2017-02-28 | -204.83% |
| 2016-11-30 | -152.19% |
| 2016-08-31 | -456.60% |
| 2016-02-29 | -613.57% |
| 2015-11-30 | -393.35% |
| 2015-08-31 | -231.64% |
| 2014-07-31 | -36.33% |
| 2014-04-30 | -20.87% |
| 2014-01-31 | -16.45% |
| 2013-10-31 | -16.37% |
| 2013-07-31 | -8.35% |
| 2013-04-30 | -2.66% |
| 2013-01-31 | -10.60% |
| 2012-10-31 | -10.39% |
| 2012-07-31 | -11.82% |
| 2012-04-30 | -26.01% |
| 2012-01-31 | -20.65% |
| 2011-10-31 | -20.22% |
| 2011-07-31 | -25.81% |
| 2011-04-30 | -20.33% |
| 2011-01-31 | -19.33% |
| 2010-10-31 | -25.65% |
| 2010-07-31 | -29.20% |
| 2010-04-30 | -37.84% |
| 2010-01-31 | -37.37% |
| 2009-10-31 | -32.80% |
| 2009-07-31 | -36.74% |
| 2009-04-30 | -31.40% |
| 2009-01-31 | -41.38% |
| 2008-10-31 | -35.42% |
| 2008-07-31 | 1.63% |
| 2008-04-30 | -36.31% |
| 2008-01-31 | -25.92% |
| 2007-10-31 | -31.10% |
| 2007-07-31 | -81.01% |
| 2007-04-30 | -46.19% |
| 2007-01-31 | -30.13% |
| 2006-10-31 | -73.17% |
